Results 161 to 170 of about 20,787 (190)

Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]

Ther Innov Regul Sci
Matsumoto M, Kumazawa R, Ishii-Watabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R, Iwagami M.   +11 more
europepmc   +1 more source

Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study. [PDF]

Diabetes Obes Metab
Car E, Habets G, Vulto AG, Heinemann L, Huys I, Simoens S.   +5 more
europepmc   +1 more source

Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management. [PDF]

Drugs
Philis-Tsimikas A, Aberle J, Bajaj H, Lingvay I, Mu Y, Shaikh S, Vianna A, Watada H, Del Prato S.   +8 more
europepmc   +1 more source

Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights. [PDF]

Ann Med Surg (Lond)
Ashraf T, Kumar A, Tara A, Memon N, Muhammad A, Turesh M, Dev S, Muhammad N, Kumar V, Hussain T, Kumar R, Singh A, Bajaj S, Qammar A, Deepak F, Kumar A, Yusuf SA.   +16 more
europepmc   +1 more source

Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Ahmed A, Tan Z, Abd El-Radi W, Rajamani K.   +3 more
europepmc   +1 more source

Efficiency of Gla-300 versus Gla-100 Across Age Groups in People Living with Type 2 Diabetes in France: A Post Hoc Analysis of an Observational Longitudinal Study. [PDF]

Adv Ther
Darmon P, Hanon O, Gourdy P, Borget I, Detournay B, Evenou P, Bureau I, Allali N, Mahieu A, Emery C, Penfornis A.   +10 more
europepmc   +1 more source

Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation.

JAMA Health Forum
Murphy SJ, Holtkamp NC.
europepmc   +1 more source